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Summary
Almost 100% of APL patients carry chimeric transcripts encoding truncated RARa fused to homo-oligomerization domains
from partner proteins. To gain further insights into the cellular transformation mechanisms mediated by RARa fusion pro-
teins, thorough structure/function analyses have been performed and identified the POZ homo-oligomerization domain
as the minimal transformation domain that is necessary and sufficient for PLZF-RARa-mediated in vitro transformation of
primary hematopoietic cells. A transformation-incompetent PLZF-RARa mutant defective in homo-oligomerization but
not corepressor interaction could be rescued by synthetic FKBP-oligomerization domains. Furthermore, an artificial
FKBP-RARa construct not only mimicked various biochemical properties of bona fide RARa fusion proteins but also medi-
ated an ATRA-dependent transformation. Taken together, these findings endorse an oligomerization-dependent mecha-
nism for RARa-mediated transformation and suggest a potential avenue for molecular therapy.Introduction
Acute myeloid leukemias (AML) are characterized by selective
expansion and differentiation block of immaturemyeloid precur-
sors carrying specific chimeric transcription factors, whichmost
commonly involve mutations of the retinoic acid receptor
a (RARa), the core binding factor subunits (AML1 or CBFb), or
the mixed lineage leukemia (MLL) protein (So and Cleary,
2004). Chimeric RARa fusion can be found in almost 100% of
acute promyelocytic leukemia (APL, AML-M3, a subtype of
AML) that are remarkably sensitive to all-trans-retinoic acid
(ATRA)-induced terminal differentiation (Zelent et al., 2001).
The molecular mechanisms underlying the ATRA treatment of
APL have been thoroughly studied in the last decade. It is now
known that, in the presence of physiological doses (1028 M) of
ATRA, RARa/RXRa heterodimers will dissociate from transcrip-
tional corepressor complexes composed of SMRT/NCoR, Sin3,
and histone deacetylase (HDAC) and associate with transcrip-
tional activation complexes consisting of CBP/p300, P/CAF,
SRC-1, TIF2, and TRAM-1 (Chen et al., 1996, 1997; Kurokawa
et al., 1995; Onate et al., 1995; Takeshita et al., 1997). This tran-
scriptional switch from repression to activation will lead to ex-
pression of specific set of RA-inducible genes and normalCANCER CELL 9, 95–108, FEBRUARY 2006 ª2006 ELSEVIER INC. DOI 1differentiation of hematopoietic progenitors (Chambon, 1996).
However, in the case of RARa fusion, the complete dissociation
with transcriptional corepressor complexes will only occur at
much higher pharmaceutical (1026 M) or superpharmaceutical
(for PLZF-RARa) concentrations, which may explain the effec-
tiveness and the differential retinoic acid response of APL
patients to ATRA treatment (Grignani et al., 1998; Guidez
et al., 1998; He et al., 1998; Lin et al., 1998). Further biochemical
analyses reveal that the homo-oligomerization (formation of
complexes with two or more identical subunits) domains pres-
ent in all RARa partners including PML, PLZF, NPM, NuMA,
and Stat5b are necessary and sufficient for the aberrant tran-
scriptional repression properties, suggesting their critical roles
in leukemic transformation (Dong et al., 1996, 2003; Dong and
Tweardy, 2002; Lin and Evans, 2000; Minucci et al., 2000; Perez
et al., 1993; Redner et al., 2000; So et al., 2000).
While significant progress has been made in understanding
the biochemical and transcriptional properties of RARa fusions,
the biological relevance of these findings in terms of transform-
ing primary hematopoietic targets is still unclear. Since overex-
pression of RARa fusions are toxic to the majority of the hema-
topoietic cell lines (Ferrucci et al., 1997), very limited structure/
function transformation studies have been performed, andS I G N I F I C A N C E
While transcription factors are frequently targeted and converted into constitutive transcriptional activators or repressors in acute leu-
kemia, acquisition of homo-oligomerization domains is a common feature associated with many oncogenic transcription factors, in-
cluding RARa fusion proteins, which are present in almost all the APL patients. We have previously shown that forced oligomerization of
truncated MLL can activate its transcriptional and oncogenic properties. Here, we further extend this finding to a different class of on-
cogenic transcriptional repressors by demonstrating that simple homo-oligomerization of RARa by either a bona fide fusion partner
(PLZF) or synthetic oligomerization (FKBP) module can lead to oncogenic transformation of primary hematopoietic cells. These studies
emphasize a prevailing and critical role for homo-oligomerization in oncogenic activation of chimeric transcription factors.0.1016/j.ccr.2006.01.005 95
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A R T I C L Ethose have mainly exploited well-established cell lines such as
U937 (Grignani et al., 1996, 1999; Lin and Evans, 2000; Ruthardt
et al., 1997), which suffer from the pitfalls of carrying multiple
nonrelevant genetic mutations that may not reflect the normal
biology of the disease. To assess the impacts of oncoproteins
on primary bonemarrow cells, a retroviral transduction/transfor-
mation assay (RTTA), which has been widely used for various
oncogenic transcription factors reported in human leukemia
(Lavau et al., 1997; Slany et al., 1998; So et al., 2003a, 2003b),
was employed to study RARa fusion proteins. Primary hemato-
poietic cells transduced with RARa fusions exhibited enhanced
in vitro self-renewal and were capable of inducing APL-like dis-
eases when transplanted into mice (Du et al., 1999; Minucci
et al., 2002). These results not only reveal the primary impact
of RARa fusion in promoting self-renewal but also provide
a more physiologically relevant system to study the transforma-
tion property of RARa fusion.
To gain further mechanistic insights into the transformation
mechanisms mediated by RARa fusion proteins, we performed
detailed structure/function analysis using RTTA and identified
the POZ homo-oligomerization domain as the minimal transfor-
mation domain for PLZF-RARa-mediated transformation of pri-
mary hematopoietic cells. We also provide experimental evi-
dence showing that forced homo-oligomerization of RARa can
mimic various biochemical properties of bona fide RARa fusion
proteins and transform primary hematopoietic cells in an ATRA-
dependent manner. Taken together, our results endorse the im-
portance of a homo-oligomerization-dependent mechanism for
RARa-mediated leukemogenic transformation.
Results
The POZ domain is the minimal transformation domain
for PLZF-RARa-mediated transformation of primary
hematopoietic cells
While we and others have shown previously that the POZ do-
main is critical for homo-oligomerization (formation of com-
plexes with two or more identical subunits) and transcriptional
activities of PLZF-RARa, its functional significance in transfor-
mation of primary hematopoietic cells has not been demon-
strated (Dong et al., 1996; Grignani et al., 1998; Guidez et al.,
1998; He et al., 1998; Hong et al., 1997; Lin et al., 1998). To
this end, the ability of PLZF-RARa to transform primary bone
marrow cells was assessed using RTTA as previously described
(Du et al., 1999; Minucci et al., 2002; So et al., 2003a, 2003b).
PML-RARa, which only has homo-oligomerization domains
but not additional SMRT interaction domains was also used as
a control in the experiment. In contrast to primary bone marrow
cells transduced with MSCV vector alone that exhausted their
self-renewal ability in the second round of plating, PLZF-CANCER CELL FEBRUARY 2006RARa- or PML-RARa-transduced cells were able to form com-
pact colonies in the third round of plating (Figure 1A). Morpho-
logical and immunophenotypic analysis of third round colonies
from both PLZF-RARa and PML-RARa were consistent with
early myeloid progenitors (c-kitlo, Mac-1+, Gr-1+, B2202,
CD32), indicating that RARa oncoproteins could enhance self-
renewal and partially arrest transduced cells at an early myeloid
progenitor stage (Figures 1B and 1C and data not shown). It is
interesting to note that, although they had similar cellular mor-
phology and immunophenotype, the number of colonies from
PLZF-RARa-transformed cells was significantly higher than
the number of colonies from cells transformed with PML-
RARa, suggesting that PLZF-RARamay be amore potent onco-
protein in conferring self-renewal ability to affected cells, which
may correlate with its enhanced ability to associate with core-
pressor complexes (e.g., SMRT) (Grignani et al., 1998; Guidez
et al., 1998; He et al., 1998; Hong et al., 1997; Lin et al., 1998).
These observed transformations were also dependent on the
functional contributions from the PLZF or PML portions as cells
transduced with a RARa 30 construct encoding the truncated
form of RARa failed to give raise third round colonies
(Figure 1A). To identify the domain required for the enhanced
in vitro self-renewal, the transformation ability of a series of de-
letion mutant constructs targeting different regions of PLZF (in-
cluding the POZ domain that overlaps with transcriptional re-
pression domain 1 [RPD1], proline-dependent phosphorylation
sites, transcriptional repression domain 2 [RPD2], two individual
Zn fingers) was assessed using RTTA (Figure 1A). Cells trans-
duced with constructs (CI-CV) containing intact POZ/RPD1 do-
main consistently generated third round colonies, suggesting
that the proline-dependent phosphorylation sites, PRD2, and
both Zn fingers were dispensable for the in vitro transformation
of primary hematopoietic cells. Conversely, constructs lacking
the POZ domain (CVII, CVIII) failed to transform, indicating that
an intact POZ domain is essential for the enhanced self-renewal
(Figure 1A). The appropriate expression of each construct was
confirmed by both Western blot and coupled in vitro transcrip-
tion/translation assays (Figures 1D and 1E). The contrasting
transformation results from CV (minimal POZ) and CVII (deletion
of POZ) constructs suggested that the POZ domain is the mini-
mal transformation domain required for enhanced in vitro self-
renewal of primary hematopoietic cells.
The POZ domain is required for homo-oligomerization,
high-affinity association with SMRT, and formation of
high-molecular weight transcriptional complexes
To further characterize the biochemical properties of the PLZF-
RARa constructs, their ability to form homo-oligomers and sta-
ble, high-molecular weight protein complexes and to interact
with the nuclear receptor transcriptional corepressor (SMRT)Figure 1. The POZ domain is the minimal transformation domain for PLZF-RARa-mediated transformation of primary hematopoietic cells
A: Schematic diagram of PLZF-RARa, PML-RARa, and the retroviral constructs used in RTTA (left). POZ, the POZ domain; RPD, repression domain; Z, zinc finger;
C3HC4, RING finger motif; B1 and B2, Cys-rich B box; coiled coil, coiled coil dimerization domain. The bar chart (right) represents the corresponding numbers of
colonies after each round of plating in methylcellulose. Error bars indicate standard deviations (SD).
B: Typical morphology (upper panel) and histological staining (lower panel) of third round colonies generated from bone marrow cells transduced with ret-
roviruses expressing transforming construct (e.g., wild-type PLZF-RARa and PML-RARa) or nontransforming construct (e.g., MSCV alone). Scale bars in upper
panel and lower panel are 100 mm and 10 mm, respectively.
C: Phenotypic analysis of cells transformed by PLZF-RARa or PML-RARa after the third plating. Blue profiles represent stainings obtained with antibodies specific
for the indicated cell surface antigens. Red profiles represent unstained controls.
D: Western blot using anti-RARa antibody showed similar level of expression of expected size proteins from each construct.
E: Appropriate protein expression from constructs used for GST pull-down was confirmed by coupled in vitro transcription/translation assay.97
A R T I C L EFigure 2. The POZ domain is required for homo-oligomerization, high-affinity association with SMRT, and formation of high-molecular weight complex by PLZF-RARa
A: Cell lysates were immunoprecipitated with anti-HIS antibody and Western blotted with anti-Flag antibody. Constructs used in cell transfection are listed in
the left.
B: 35S-labeled PLZF-RARa constructs indicated in the left were incubated with GST beads, GST-SMRT, or GST-TRAM-1 in the absence or presence of indicated
amount of ATRA.
C: 293 cells cotransfected with Flag-tagged SMRT and HIS-tagged PLZF-RARa constructs were immunoprecipitated with anti-HIS antibody and Western blot-
ted with anti-Flag antibody in the absence or presence of ATRA treatment. Constructs used for transfection are listed in the left.
D: KG1 cells transfected with Flag-tagged PLZF-RARa constructs were immunoprecipitated with anti-Flag antibody and Western blotted with anti-SMRT anti-
body in the absence or presence of ATRA treatment. Constructs used for transfection are listed in the left. Mock-transfected control was also indicated.
E and F: Mammalian two-hybrid assay using COS7 cells cotransfected with different pVP16(TA)-PLZF-RARa mutants in combination with GAL4-TK-luciferase
reporter, Renilla luciferase internal control, and pGAL4-(DBD)-SMRT (E) or pGAL4-(DBD)-TRAM-1 (F). Transfected cells were cultured in DMEM supplement98 CANCER CELL FEBRUARY 2006
A R T I C L Eand coactivator (TRAM-1) were studied. To assess their ability to
form homo-oligomers, PLZF-RARa constructs were tagged
with either Flag epitope or His epitope and cotransfected into
293 cells for immunoprecipitation assays. As a result, homo-
oligomers were observed in both full-length PLZF-RARa and
CV but not CVII mutant, confirming that the POZ domain is nec-
essary and sufficient for mediating homo-oligomerization of
PLZF-RARa oncoproteins (Figure 2A). Next, their ability to inter-
act with transcriptional corepressor and coactivator was as-
sessed using a GST pull-down assay with wild-type RARa as
a control. In the absence of ATRA, PLZF-RARa was apparently
most efficiently captured by the SMRT affinity beads, while CVII
mutant and wild-type RARa lacking the POZ domain were least
well bound, indicating that the POZ homo-oligomerization en-
hanced the binding to SMRT. When treated with increasing
amounts of ATRA, CVII started to associate with TRAM-1 at
1028 M ATRA and completely dissociated from SMRT at 1027
M ATRA (Figure 2B). Conversely, although their association
with TRAM-1 started at 1028 M ATRA, the dissociation of
SMRT from full-length PLZF-RARa and CV only occurred at
1027 M and 1026 M ATRA, respectively (Figure 2B). To confirm
these interactions in vivo, both immunoprecipitation assays
and a mammalian two-hybrid assay were employed. 293 cells
cotransfected with Flag-tagged SMRT and different HIS-tagged
PLZF-RARa constructs were immunoprecipitated with anti-HIS
antibody and then subjected to Western blot using anti-Flag an-
tibody. As expected, the specific band corresponding to SMRT
protein was precipitated by anti-HIS antibody when cells were
cotransfected with HIS-tagged PLZF-RARa constructs (Fig-
ure 2C). When treated with 1027 M ATRA, SMRT dissociated
from CVII but not from PLZF-RARa or CV, confirming the in vitro
GST pull-down data. To demonstrate these interactions in leu-
kemic cells, we transfected KG1 cells that express high level
of SMRT with various Flag-tagged PLZF-RARa constructs for
immunoprecipitation analysis using anti-Flag antibody. Endoge-
nous SMRT protein was only precipitated in cells transfected
with Flag-tagged PLZF-RARa construct but not in mock-trans-
fected cells (Figure 2D). Consistently, endogenous SMRT com-
pletely dissociated from CVII but not from PLZF-RARa or CV in
the presence of 1027 M ATRA (Figure 2D), indicating strong co-
repressor binding associated with the POZ domain in leukemic
cells context. To confirm these interactions in living cells, mam-
malian two-hybrid assays were performed using COS7 cells co-
transfected with pGAL4(DBD)-SMRT or pGAL4(DBD)-TRAM-1
in combination with pVP16(TA)-PLZF-RARa mutants and
pGAL4-TK-luciferase reporter. As a result, all PLZF-RARa mu-
tants including CVII with weaker SMRT binding affinity can inter-
act with SMRT and activate the reporter activity in vivo
(Figure 2E). Both PLZF-RARa and CV resulted in around 8-fold
activation, while CVII only had 5 folds as compared with vector
control. When cells were treated with increasing amount ATRA,
the SMRT interaction started to dissociate (Figure 2E). But both
PLZF-RARa and CV could still maintain at least 2-fold activation
even in the presence of 1026 M ATRA. Conversely, the interac-
tion between CVII and SMRT was very sensitive to ATRACANCER CELL FEBRUARY 2006treatment and was almost completely disrupted in the presence
of 1028 M ATRA (Figure 2E). On the other hand, the in vivo
TRAM-1 association was far more prominent with CVII than
with PLZF-RARa or CV (Figure 2F). CVII and TRAM-1 exhibited
strong in vivo interaction and resulted in over 10-fold reporter
activation, while PLZF-RARa and CV were only weakly associ-
ated with TRAM-1 and had activity just above (<2 folds) the
basal level of the vector control (Figure 2F). In the presence of
ATRA, CVII responded swiftly and resulted in almost 60-fold in-
duction at 1028 M ATRA and reached almost 80 folds in the
presence of 1026 M ATRA (Figure 2F). In contrast, PLZF-RARa
was almost inert to the treatment and only had 3-fold activities
in the presence of 1026 M ATRA. In response to ATRA, CV
had noticeable butmild induction and reached about 10-fold ac-
tivation at 1026 M ATRA (Figure 2F). Taken together, these re-
sults are consistent with the in vitro binding data indicating
that the POZ oligomerization domain confers preferential
binding ability to transcriptional corepressor (SMRT) over coac-
tivator (TRAM-1) in an ATRA-dependent manner. Finally, we
assessed the ability of thesemutants to form stable high-molec-
ular weight transcriptional complexes, which has been pro-
posed as a critical feature for RARa oncoproteins (Lin and
Evans, 2000; Minucci et al., 2000). Using gel filtration, we dem-
onstrated that almost the entire population of full-length PLZF-
RARa protein with apparent monomeric size of about 120 kDa
was eluted at much higher-molecular weight fractions of about
400 kDa (Figure 2G). Similarly, CV with monomeric size of only
about 65 kDa (Figure 1E) was capable of forming high-molecular
weight complexes with slightly smaller estimated size, which
probably reflects the reduced size of the mutant proteins. This
suggest that both full-length PLZF-RARa and CV can form sim-
ilar stable multiprotein transcriptional complexes, although
a smaller subpeakwith apparent molecular size similar to homo-
dimers was only noticed in CV (Figure 2G). In marked contrast,
almost the entire population of CVII protein lacking the POZ do-
main was eluted at fractions of apparent molecular weight less
than 100 kDa (Figure 2G), which is consistent with the size of
a monomer (Figure 1E). Taken together, these data indicated
that the POZ domain is required for enhanced self-renewal,
homo-oligomerization, efficient interaction with transcriptional
coregulators, and formation of stable high-molecular weight
complexes mediated by PLZF-RARa oncoprotein.
A POZ point mutant disrupting homo-oligomerization
but not SMRT interaction results in loss of
transformation potential
Complete removal of the POZ domain (CVII, CVIII) might affect
the overall architecture and result in protein misfolding, which
in turn could lead to the observed transformation and biochem-
ical defects. Taking advantage of the X-ray crystallographic
structure data available for the POZ domain of PLZF (Melnick
et al., 2000, 2002), we made more sophisticated point mutants
that maintain appropriate protein folding but selectively disrupt
homo-oligomerization and/or repressor interaction. The integrity
of the charged pocket in the POZ domain is critical for properwith 10% charcoal/dextran-treated FCS in the absence or presence of indicated ATRA for 24 hr before cell lysis. Fruit fly luciferase activities normalized with
Renilla luciferase activity were plotted as folds of induction compared with vector control-transfected cells. Error bars indicate standard deviations (SD).
G: Gel filtration analysis of PLZF-RARa mutants. Top panel indicates the Western blot results using anti-RARa antibody on protein fractions collected from in-
dicated elution volumes (ml). Constructs used in the experiments are shown in the left. Bottom panel is the gel filtration chromatogram plotting elution volume
(ml) against the relative band intensity of the detected proteins compared with the strongest protein band. Arrows indicate elution volumes of the corre-
sponding size standard.99
A R T I C L EFigure 3. Self-association-defective point mutant can interact with corepressor but fails to enhance self-renewal of transduced primary hematopoietic bone
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A R T I C L Efolding and transcription repression (Melnick et al., 2000, 2002).
In the context of PLZF, a double mutant carrying mutations of
aspartic acid 35 to asparagine and arginine 49 to glutamine
(D35N/R49Q) has proper folding but almost completely loses re-
pression ability. Conversely, a D35N mutant carrying a single
mutation of aspartic acid 35 to asparagine maintains most of
the original properties of the wild type PLZF-RARa including
transcription repression ability, albeit with an exception of
slightly reduced ability to form homo-oligomer (Melnick et al.,
2000, 2002). These mutants thus provided unique opportunities
to study the functional requirement of homo-oligomerization
in PLZF-RARa-mediated transformation. To this end, PLZF-
RARa constructs carrying these mutations were made and
assessed for their ability to transform primary hematopoietic
progenitors, form homo-oligomers, high-molecular weight com-
plexes, and interact with transcription corepressors and coacti-
vators. In addition, an alanine PLZF-RARamutant (Ala48–52) that
forms misfolded protein was also made and used as a negative
control for the assay (Melnick et al., 2000, 2002). As expected,
themisfolded Ala mutant was not able to transform primary cells
(Figure 3A). Interestingly, the PLZF-RARa (D35N/R49Q) double
mutant also lost its colony-forming ability in the third round of
plating, although a similar number of colonies was obtained in
the initial plating (Figure 3A and data not shown). Conversely,
the PLZF-RARa (D35N) single mutant was still capable of form-
ing compact third round colonies, although the numbers were
significantly reduced (Figure 3A). The appropriate expression
of each construct in packaging cells was confirmed by Western
blot and coupled in vitro transcription/translation (Figure 3B
and 1E).
To assess the biochemical properties of these mutants, GST
pull-down revealed similar but distinctive in vitro binding proper-
ties of both D35N and D35N/R49Q mutants to SMRT and
TRAM-1 (Figure 3C). While both mutants could associate with
SMRT, the D35N/R49Q mutant had slightly higher binding affin-
ity to SMRT than the D35Nmutant that exhibited a weaker initial
SMRT capture as compared with the wild-type PLZF-RARa,
whichmay partially account for theweaker transformation ability
exhibited by the D35N mutant (Figure 3C). In response to ATRA
treatment, although both mutants started to associate with
TRAM-1 at 1028 M ATRA, significant dissociations of SMRT
from D35N and D35N/R49Q mutants were only observed at
1027 M and 1026 M ATRA, respectively (Figure 3C). While the
SMRT binding property of the D35N/R49Q mutant was different
from the reported mutant in the context of PLZF, this finding is
consistent with a recent report showing a strong corepressor
binding ability by this D35N/R49Q mutant in the context of
PLZF-RARa (Puccetti et al., 2005), suggesting that the core-
pressor binding is probably through the RARa portion or/and
created as a result of novel protein folding when it is fused
with RARa. When their ability to form high-molecular weightCANCER CELL FEBRUARY 2006complexes was assessed, the D35N mutant displayed a very
similar pattern as the wild-type PLZF-RARa with a single peak
at about 400 kDa, while the D35N/R49Q mutant protein was al-
most exclusively eluted in the fractions with apparent molecular
size smaller than 120 kDa, although a very small fraction of high-
molecular weight complex was observed under long exposure
(Figure 3D and data not shown). Taken together, these results
further indicate that formation of stable high-molecular weight
complexes via the homo-oligomerization domain is critical for
cellular transformation mediated by PLZF-RARa.
Forced oligomerization of RARa rescues the
transformation phenotype of the PLZF-RARa
D35N/R49Q mutant
To ascertain the role of homo-oligomerization in PLZF-RARa-
mediated transformation, we tested if resurrection of the oligo-
merization ability of the PLZF-RARa D35N/R49Q mutant
(FKBP-D35N/R49Q) by a potent synthetic oligomerization mod-
ule FKBP (M36) could rescue the transformation phenotype.
Both the biochemical and transformation properties of FKBP-
D35N/R49Q mutants were assessed. Analogous to the original
PLZF-RARa D35N/R49Q mutant, FKBP-D35N/R49Q associ-
ated with TRAM-1 at 1028 M ATRA and dissociated from
SMRT at 1026 M ATRA (Figure 4A). Conversely, FKBP conferred
strong homo-oligomerization ability to the otherwise self-asso-
ciation-deficient PLZF-RARaD35N/R49Qmutant. FKBP-D35N/
R49Q could efficiently self-associate in the immunoprecipitation
assay where PLZF-RARa D35N/R49Q was compromised in
forming homo-oligomers (Figure 4B). Similarly, high-molecular
weight complexes reappeared in gel filtration analysis when
FKBP was fused to the otherwise monomeric FKBP-D35N/
R49Q mutant (Figure 4C). Since the apparent molecular size of
a monomeric FKBP-D35N/R49Q mutant is about 200 kDa (Fig-
ure 1E), the two major high-molecular weight peaks with appar-
ent molecular sizes of about 550 kDa and 800 kDa are compa-
rable to the expected size of homodimers and homotetramers,
respectively, suggesting that FKBP-D35N/R49Q may associate
with more heterogeneous homo-oligomeric high-molecular
weight complexes, which has also been noticed in CV (Fig-
ure 2G). Taken together, these findings suggest that FKBP sig-
nificantly enhanced the ability of D35N/R49Q to self-associate
and form stable high-molecular weight complexes without dra-
matically affecting other biochemical properties. Before these
constructs were tested in RTTA for their ability to transform pri-
mary hematopoietic cells, their expression was also confirmed
byWestern blotting and coupled in vitro transcription/translation
assay (Figures 3B and 1E). In contrast to the PLZF-RARa D35N/
R49Q mutant that failed to sustain replating after the second
round of plating, cells transduced with FKBP-D35N/R49Q
were capable of forming a significant number of third round
compact colonies with morphology similar to that of wild-typeA: Schematic diagram of PLZF-RARa constructs used in RTTA (left). ZR, PLZF-RARa. The bar chart (right) represents the corresponding numbers of colonies in the
third round plating. Error bars indicate standard deviations (SD). Pictures showed typical morphology of the third round colonies from bone marrow cells trans-
duced with retroviruses expressing the indicated construct. Scale bars, 100 mm.
B: Western blot using anti-RARa antibody showed similar level of expression of expected size proteins from each construct in packaging cells.
C: 35S-labeled PLZF-RARa constructs indicated in the left column were incubated with GST beads, GST-SMRT, or GST-TRAM-1 in the absence or presence of
indicated amount of ATRA.
D: Gel filtration analysis. Top panel shows the Western blot using anti-RARa antibody on protein fractions collected from indicated elution volumes (ml). Con-
structs used in the experiments are shown in the left. Bottom panel is the gel filtration chromatogram plotting elution volume (ml) against the intensity of the
detected proteins with arrows indicating the elution volumes of the corresponding size standard.101
A R T I C L EFigure 4. Rescue of transformation phenotype of self-association-defective point mutant by synthetic FKBP homo-oligomerization module
A: 35S-labeled PLZF-RARa mutant constructs indicated in the left were incubated with GST beads, GST-SMRT, or GST-TRAM-1 in the absence or presence of
indicated amount of ATRA. The same ZR-D35N/R49Q panel from Figure 3C was used in this figure for comparison, as these experiments were performed at
the same time. ZR, PLZF-RARa.
B: Lysates extracted from 293 cells transfected with constructs shown in the left were immunoprecipitated with anti-HIS antibody and Western blotted with
anti-Flag antibody.
C: Gel filtration analysis indicates reappearance of high-molecular weight complexes associated with FKBP-PLZF-RARa D35N/R49Q mutant. Top panel shows
the Western blot using anti-RARa antibody on protein fractions collected from indicated elution volumes (ml). Constructs used in the experiments are shown in
the left. Bottom panel is the gel filtration chromatogram plotting elution volume (ml) against the relative band intensity of the detected proteins with arrows
indicating the elution volumes of the corresponding size standard.102 CANCER CELL FEBRUARY 2006
A R T I C L EPLZF-RARa-transformed cells in spite of being fewer in number
(Figures 4D and 4E). To further characterize the FKBP-D35N/
R49Q-transformed cells, FACS analysis revealed immunophe-
notypes of myeloid precursor (c-kitlo, Mac-1+, Gr-1+) that were
very similar to the wild-type PLZF-RARa-transformed cells (Fig-
ures 4F and 1C).
Forced oligomerization of RARa is sufficient to mimic
bona fide chimeric RARa oncoproteins in transforming
primary hematopoietic cells
The successful albeit partial rescue of the PLZF-RARa D35N/
R49Q mutant by chimeric fusion with the FKBP oligomerization
domain further endorses a key role of homo-oligomerization in
RARa-mediated transformation. To this end, we tested if forced
homo-oligomerization of RARa itself would be sufficient to
transform hematopoietic progenitors in vitro. A FKBP-RARa
synthetic construct was made by fusing FKBP directly to the
50 truncated RARa, which was assessed for both its biochemical
and transformation properties. FKBP-RARa was capable of
forming strong homo-oligomers (Figure 5A) and stable high-mo-
lecular weight complexes with a major peak of apparent molec-
ular weight of about 250 kDa (Figure 5B). FKBP-RARa also inter-
acted with SMRT and TRAM-1 in an ATRA-dependent manner
with similar or even slightly stronger binding affinities compared
with wild-type PLZF-RARa (Figure 5C). These results indicate
that FKBP-RARa closely mimics various biochemical properties
of bona fide RARa oncoproteins.
When FKBP-RARa was expressed (Figures 1E and 3B) and
tested in RTTA, it was capable of enhancing self-renewal of
transduced primary hematopoietic cells and formed compact
colonies in the third round of plating (Figure 5D). Consistently,
the FKBP-RARa-transformed cells had very similar colony mor-
phology and immunophenotypes to those of PLZF-RARa-trans-
formed cells and were positive for Mac-1, Gr-1, and c-kit but
negative for CD3 and B220 (Figures 5E and 5F and data not
shown). To demonstrate the FKBP-RARa-mediated transforma-
tion acting on the same or similar pathways as the bona fide
RARa fusion proteins, FKBP-RARa-transformed cells were
treated with ATRA to see if the transformation could be reversed
by intervening the retinoid pathways, which aremajor character-
istics associated with RARa fusion-mediated transformation. As
a control, cells transformed by a non-APL oncoprotein, E2A-
PBX, were also included in the assay. In contrast to E2A-PBX-
transformed cells that were refractory to ATRA treatment, the
numbers of compact colonies after the third round of plating
were significantly reduced when FKBP-RARa cells were treated
with 1028 M ATRA (Figure 5D). The size of the residual colonies
after the ATRA treatment was also substantially smaller than the
untreated counterpart (Figure 5F). The colony numbers further
reduced with increasing dosage of ATRA and were almost com-
pletely eliminated when the concentration of ATRA reached the
pharmaceutical dose of 1026 M (Figure 5D). Taken together,
these data indicate that forced homo-oligomerization of RARaCANCER CELL FEBRUARY 2006can mimic various biochemical properties of bona fide RARa fu-
sion proteins and transform primary hematopoietic cells in an
ATRA-dependent manner.
Finally, we also investigated if homo-oligomerization is
required formaintenance of transformation phenotype by FKBP-
RARa. To this end, we tried to reverse the transformation by dis-
sociating homo-oligomerization in cells transduced with FKBP-
RARa using the FKBP homo-oligomer inhibitor drug AP21998.
The effectiveness of AP21998 drug to dissociate FKBP-medi-
ated homo-oligomerization was demonstrated by immunopre-
cipitation assay (Figure 5A) and further confirmed by gel filtration
analysis where FKBP-RARa was eluted as mainly a monomeric
fraction at around 100 kDa upon 1 mM AP21998 treatment
(Figure 5B). To assess the effect of the drug on cell transforma-
tion, FKBP-RARa-transduced cells after the first plating were
split into two, and half of themwere treatedwith two consecutive
rounds of AP21998. PLZF-RARa-transduced cells were used as
a control for specificity and general toxicity of the drug in the
assay. As a result, almost identical numbers of colonies were
obtained in PLZF-RARa-transduced cells with or without the
drug, indicating that the level of drug used was not generally
toxic to cells (Figure 5D). Conversely, the numbers of third round
colonies were significantly reduced when FKBP-RARa-trans-
formed cells were treated with the drug (Figure 5D). Although
complete inhibition had not be achieved, probably due to the
poor accessibility of the drug in methylcellulose to the affected
cells, the significant reduction of the transformed colony by
AP21998 suggests a critical function of homo-oligomerization
in maintaining the cellular transformation phenotypes.
Discussion
While forced homo-oligomerization is a well-known oncogenic
mechanism to activate protein tyrosine kinases in chronic leuke-
mias, myeloproliferative syndromes, and other malignances, its
functional relevance in activating oncogenic transcription fac-
tors has not been clearly established (So and Cleary, 2004).
We and others have recently shown that homo-oligomerization
contributes to oncogenic activation of MLL in acute leukemias,
where MLL chimeras are believed to act as constitutive tran-
scriptional activators that aberrantly maintain expression of
downstream target genes (Eguchi et al., 2004; Martin et al.,
2003; So et al., 2003b). Here, we extend this finding to an oppo-
site class of oncogenic transcription factors (e.g., RARa) with
constitutive transcription repression activity. In contrast to
MLL chimeras, RARa oncoproteins recruit transcriptional core-
pressor complexes that suppress expression of target genes,
which are critical for self-renewal, cell differentiation, and/or ap-
optosis (Zelent et al., 2001). To understand the molecular mech-
anisms leading to oncogenic conversion of RARa by fusion pro-
teins, we showed that the POZ homo-oligomerization domain of
PLZF is necessary and sufficient when fused with RARa to en-
hance self-renewal and inhibit differentiation of primaryD: Schematic diagram of PLZF-RARa constructs used in RTTA (left). The bar chart (right) represents the corresponding numbers of colonies after the third round
of plating in methylcellulose. Error bars indicate standard deviations (SD).
E: Typical morphology of the third round colonies generated from bone marrow cells transduced with retroviruses expressing indicated construct. Scale bars,
100 mm.
F: Phenotypic analysis of cells transformed by FKBP-PLZF-RARa D35N/R49Q after the third plating. Dotted profiles represent stainings obtained with antibodies
specific for the indicated cell surface antigens. Zebra-plotted profiles represent unstained control.103
A R T I C L EFigure 5. Forced homo-oligomerization of RARa results in transformation of primary myeloid progenitors in an ATRA-dependent manner
A: Lysates extracted from 293 cells transfected with constructs shown in the left were immunoprecipitated with anti-HIS antibody and Western blotted with
anti-Flag antibody.
B: Gel filtration analysis of FKBP-RARa in the absence or presence of AP21998. Gel filtration chromatogram plotted elution volume (ml) against the intensity of
the specific detected band with arrows indicating elution volumes of the corresponding size standard.
C: 35S-labeled RARamutant constructs indicated in the left were incubated with GST beads, GST-SMRT, or GST-TRAM-1 in the absence or presence of indicated
amount of ATRA.104 CANCER CELL FEBRUARY 2006
A R T I C L Ehematopoietic cells. Restoration of the homo-oligomerization
capacity to the PLZF-RARa D35N/R49Q point mutant rescues
the transformation phenotype, indicating that homo-oligomeri-
zation is an integral part of PLZF-RARa-mediated transforma-
tion. To this end, we further demonstrated that synthetic
homo-oligomerization of truncated RARa (FKBP-RARa) mimics
many biochemical properties of bona fide RARa oncoproteins
and is sufficient to induce differentiation block on primary mye-
loid precursors. This transformation can also be partially re-
versed by either the specific homo-oligomerization inhibitor
drug AP21998 or retinoic acid treatment. Collectively, these re-
sults emphasize a critical functional link between homo-oligo-
merization and transformation of primary hematopoietic cells
by RARa oncoproteins.
Homo-oligomerization is a widely used and crucial mecha-
nism for regulation of various normal biological processes
from enzymatic activation and signal transduction to gene ex-
pression (Marianayagam et al., 2004); however, its precise con-
tributions to the mode of action of chimeric transcription factors
remain uncertain. Homo-oligomerization can not only enhance
binding ability to existing interacting proteins/cofactors and
downstream target genes, but also create novel binding inter-
faces to new target proteins and DNA sequences (Marianaya-
gam et al., 2004). It is interesting to note that the transforma-
tion-defective PLZF-RARa D35N/R49Q point mutant exhibited
in vitro binding properties similar to those of transcriptional co-
repressor SMRT and transcriptional coactivator TRAM-1 as
compared with the rescued FKBP D35N/R49Q mutant, sug-
gesting that recruitment of other complex components that
were deficient in the PLZF-RARaD35N/R49Qmutantmay be re-
quired for cellular transformation. In addition, the aberrant re-
cruitment of critical components of transcriptional machinery
by RARa oligomers may also have dominant-negative effects
on other pathways that heavily rely on some of the limiting tran-
scriptional cofactors (Dong et al., 1996, 2003; Dong and
Tweardy, 2002; Lin and Evans, 2000; Minucci et al., 2000; Perez
et al., 1993; Redner et al., 2000; So et al., 2000). Besides, the
ability of oligomerization to increase the binding affinity of
RARa to a broader range of DNA sequences may also result in
deregulation of other downstream target genes. This is consis-
tent with a recent study showing that PML-RARa oligomers
not only have higher binding affinity to known retinoic acid re-
sponse elements (RAREs) but also possess strong binding abil-
ity to a large number of other target sequences (Kamashev et al.,
2004), suggesting that the gain of function via homo-oligomeri-
zation of RARa leading to deregulation of novel target genes
may be critical for transformation. Thus, homo-oligomerization
may act as a universal oncogenic amplifier that can not only en-
hance and/or alter the transcriptional properties of oncogenic
transcription factors by both augmenting and broadening the
binding affinity to interacting proteins and target DNA se-
quences, but also exert dominant-negative effects on other
critical pathways. Future studies to identify transcriptional
complexes and DNA binding selectivity associated with homo-CANCER CELL FEBRUARY 2006oligomerized RARa will shed significant insights into these
issues.
Previous studies showed that forced homo-oligomerization of
truncated MLL by synthetic modules contributes but is not suf-
ficient to induce rapid leukemic onset in vivo, which probably is
due to the lack of additional functions contributed by the bona
fide partners (Martin et al., 2003; So et al., 2003b). We also an-
ticipate that synthetic homo-oligomerization of truncated RARa
per se, although transforming in vitro, may not have all the onco-
genic functions of bona fide RARa fusion proteins. (1) Most of
the RARa partners, including PML, PLZF, and NPM, have
been reported to have tumor suppressor or growth-suppressive
activities (Falini et al., 2005; Felicetti et al., 2004; Grisendi et al.,
2005; McConnell et al., 2003; Pandolfi, 2001). Acquisition of
oligomerization domains from these bona fide partners will
have dominant-negative effects on the tumor suppressor func-
tions of these partner proteins by sequestering them into differ-
ent subcellular compartments (Pandolfi, 2001). (2) The oligomer-
ization domains of certain RARa partners, including PLZF and
Stat5b, have been shown to possess independent repressor in-
teraction domains that can significantly enhance corepressor
binding, which may also be responsible for their refractory re-
sponse to pharmaceutical level of ATRA treatment (Grignani
et al., 1998; Guidez et al., 1998; He et al., 1998; Lin et al.,
1998;Maurer et al., 2002; Nakajima et al., 2001). In addition, crit-
ical domains, such as the sumoylation site recently reported in
PML, that are important for Daxx repressor recruitment and
transformation will be absent in the synthetic homo-oligomeric
RARa fusion (Zhu et al., 2005). (3) Hetero-oligomers (e.g.,
PLZF-RARa with PLZF) mediated by the bona fide oligomeriza-
tion domain may also have different ability to interact with other
components of the transcriptional complexes (e.g., RXR) that
are critical for transformation (Kamashev et al., 2004). (4)
Some of the reciprocal RARa-X proteins (e.g., RARa-PLZF,
RARa-PML) have been demonstrated to be necessary to effi-
ciently induce APL in vivo (He et al., 2000; Pollock et al.,
1999). The lack of all these critical components in the synthetic
FKBP-RARa fusion will predict a weak oncogenic property,
which is also consistent with the recent observation that trans-
genic mice expressing synthetic RARa-dimers (using p50 or
FKBP homo-oligomerization domains) developed leukemia
with reduced penetrance and extended latency (Sternsdorf
et al., 2006, this issue of Cancer Cell). Thus, homo-oligomeriza-
tion is a critical but probably not the only component for RARa-
mediated leukemogenesis.
Taken together, our results indicate that forced homo-oligo-
merization of truncated RARa can mimic many biochemical
and transformation properties of bona fide RARa oncoproteins.
The absolute requirement of homo-oligomerization domain for
in vitro transformation of primary hematopoietic cells and its
ability to rescue the transformation-defective PLZF-RARa
mutant suggest its essential function for leukemogenic transfor-
mation, whichmay represent a promising avenue for therapeutic
intervention.D: Schematic diagram of retroviral constructs used in RTTA (left). Bar chart at the left represents the corresponding numbers of colonies after the third round of
plating in the absence or presence of ATRA as indicated. Right bar chart represents the corresponding numbers of colonies after the third round of plating in
the absence or presence of AP21998. Error bars indicate standard deviations (SD).
E: Phenotypic analysis of cells transformed by FKBP-RARa after the third plating. Dotted profiles represent stainings obtained with antibodies specific for the
indicated cell surface antigens. Zebra-plotted profiles represent unstained control.
F: Typical morphology of the third round colonies generated from bone marrow cells transduced with retroviruses expressing FKBP-RARa in the absence or
presence of ATRA. Scale bars, 100 mm.105
A R T I C L EExperimental procedures
Constructs
Mammalian and in vitro expression plasmids encoding full-length and vari-
ous mutants of PLZF-RARa, PML-RARa, RARa, and RXRa constructed in
pSG5 or pcDNA4 vectors have been previously described (Dong et al.,
1996; Melnick et al., 2000, 2002; So et al., 2000). Inducible homo-oligomer-
ization FKBP-RARa or FKBP-PLZF (D35N)-RARa, FKBP-PLZF (D35N/
R49Q)-RARa synthetic constructs were made by fusing four to eight tan-
dem repeats of self-oligomerizing FKBP mutant (FKBP36M) carrying Phe
to Met mutation (Ariad Pharmaceuticals, Inc.) (http://www.ariad.com/
regulationkits/) to the RARa or PLZF-RARamutant cDNAs, respectively. Ret-
roviral constructs were made by transferring the inserts from the above ex-
pression plasmids into MSCV-hygro or MSCV-puro vectors (So et al.,
2003b). GST-SMRT and GST-TRAM-1 have been previously reported
(Dong and Tweardy, 2002)
RTTA
RTTA was performed as previously described (So et al., 2003b). Briefly, viral
supernatants were collected 60 hr after transfection of Phoenix cells and
used to infect hematopoietic progenitors and stem cells that were positively
selected for c-Kit expression by magnetic activated cell sorting (MACS). Do-
nor cells were harvested from the bone marrows of 4- to 10-week-old wild-
type C57BL/6 mice. After spinoculation by centrifugation at 500 3 g for 2
hr at 32ºC, transduced cells were plated in 1% methylcellulose (Stem Cell
Technologies, Vancouver, BC, Canada) supplemented with 20 ng/ml stem
cell factor (SCF) and 10 ng/ml each of IL-3, IL-6, andGM-CSF (R&D Systems,
Minneapolis, MN) in the presence or absence of appropriate drug selection
(i.e., 1 mg/ml hygromycin or 1 mg/ml puromycin). Replating was repeated ev-
ery 7 days. For drug studies, transduced cells were split into two wells after
second plating. The homo-oligomerization inhibitor drug AP21998 was
added to a final concentration of 1–5 mM in half of the wells to assess the ef-
fect of the drug on colony formation. Alternatively, appropriate amounts of
ATRA were added to half of the wells to assess the effect on transformation.
Transformation results were determined from at least two independent ex-
periments.
Phenotype analysis
Immunophenotypic analysis was performed by FACS using fluorochrome-
conjugatedmonoclonal antibodies to c-Kit (2B8 clone), Mac-1 (M1/70 clone),
Gr-1 (RB6-8C5 clone), B220 (RA3-6B2 clone), and CD3e (145-2C11 clone)
(Pharmingen Inc. or eBiosciences Inc., San Diego, CA). Staining was gener-
ally performed on ice for 15 min. Cells were washed twice in stainingmedium
and resuspended in 1 mg/ml propidium iodine (PI) before analysis using
a FACSCalibur machine (Becton Dickinson Inc.). Dead cells were gated out
by high-PI staining and forward light scatter.
In vitro and in vivo interaction assays
GST pull-down and immunoprecipitation studies were essentially performed
as previously described (Dong and Tweardy, 2002; He et al., 1998; So et al.,
2000, 2003b). The antibodies used in the immunoprecipitation assay were
from Sigma-Aldrich (M2 anti-Flag antibody) and Santa Cruz Biotech (anti-
His antibody, anti-SMRT antibody). Mammalian two-hybrid analyses were
performed as previously described (Guidez et al., 1998). Briefly, 0.4 mg
GAL4(DBD)-SMRT or GAL4(DBD)-TRAM-1 expression vector was cotrans-
fected with (1) 0.1 mg pGAL4-TK-Luc reporter containing five consensus
GAL4 binding sites and thymidine kinase promoter upstream of the fruit fly
luciferase gene and (2) 0.1 mg pRL-CMV internal control with Renilla lucifer-
ase driven by a CMV promoter, in combination with (3) 0.4 mg different
pVP16 constructs encoding potent VP16 transactivation domain fused to
PLZF-RARa mutants. Transfected cells were treated with different concen-
trations of ATRA for 24 hr before analysis. The relative fruit fly luciferase
values were normalized with Renilla luciferase activity and presented as folds
of induction compared with pVP16 empty vector controls. Standard devia-
tions were calculated from three independent experiments.
Gel filtration study
293 cells were transfected in 10 cm plates with 20 mg of expression plasmid
encoding the analyzed proteins. Forty-eight hours posttransfection, nuclear
extracts were prepared in a high-salt elution buffer (500 mM NaCl, 20 mM106HEPES [pH 7.5], 0.5 mM EDTA, 0.1% Triton X-100, 2 mM DTT, 0.2 mM
PMSF, and protease inhibitor cocktail from Sigma). Gel filtration was carried
out using an A¨KTAFPLC system with Superdex 200 gel filtration column (1.63
60 cm; Amersham Pharmacia) preequilibrated with running buffer (0.05 M
TrisCl [pH 7.6], 200 mM NaCl, 3 mM EDTA, 0.2 mM PMSF) at a flow rate of
0.5 ml/min. Collected fractions were concentrated using the Howe Gyro-
Vap evaporator before being analyzed on 10% SDS-PAGE gels and blotted
onto nitrocellulose membranes for Western blot detection using anti-RARa
C-20 polyclonal antibody (Santa Cruz Biotech).
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